Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology - Canada
doi 10.3747/co.26.5421
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Related search

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Direct Costs Associated With Relapsed Diffuse Large B‐Cell Lymphoma Therapies

Oncologist
Cancer ResearchMedicineOncology
2019English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology
Hematology
2019English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy